A subset of multiple myeloma harboring the t(4;14)(p16;q32) translocation lacks FGFR3 expression but maintains an IGH/MMSET fusion transcript
about
sameAs
The level of TACI gene expression in myeloma cells is associated with a signature of microenvironment dependence versus a plasmablastic signatureOverexpression of transcripts originating from the MMSET locus characterizes all t(4;14)(p16;q32)-positive multiple myeloma patientsDysregulation of protein methyltransferases in human cancer: An emerging target class for anticancer therapyGain-of-function mutation of chromatin regulators as a tumorigenic mechanism and an opportunity for therapeutic interventionSmall molecule FGF receptor inhibitors block FGFR-dependent urothelial carcinoma growth in vitro and in vivo.Identification of ID-1 as a potential target gene of MMSET in multiple myelomaEvaluating gene expression profiling by quantitative polymerase chain reaction to develop a clinically feasible test for outcome prediction in multiple myelomaPreclinical studies of fibroblast growth factor receptor 3 as a therapeutic target in multiple myelomaA mechanistic rationale for MEK inhibitor therapy in myeloma based on blockade of MAF oncogene expression.In multiple myeloma, 14q32 translocations are nonrandom chromosomal fusions driving high expression levels of the respective partner genes.MMSET: role and therapeutic opportunities in multiple myeloma.Histone methyltransferase MMSET/NSD2 alters EZH2 binding and reprograms the myeloma epigenome through global and focal changes in H3K36 and H3K27 methylationThe Fibroblast Growth Factor signaling pathwayThe molecular classification of multiple myelomaThe MMSET histone methyl transferase switches global histone methylation and alters gene expression in t(4;14) multiple myeloma cells.A high-risk signature for patients with multiple myeloma established from the molecular classification of human myeloma cell linesInterpreting the molecular biology and clinical behavior of multiple myeloma in the context of global gene expression profiling.Genetics of multiple myeloma: another heterogeneity level?Role of additional chromosomal changes in the prognostic value of t(4;14) and del(17p) in multiple myeloma: the IFM experienceNSD2 links dimethylation of histone H3 at lysine 36 to oncogenic programming.Genetic heterogeneity in multiple myeloma.Genetic events in the pathogenesis of multiple myeloma.The multiple myeloma associated MMSET gene contributes to cellular adhesion, clonogenic growth, and tumorigenicity.Targeting EZH2 and PRC2 dependence as novel anticancer therapy.Microarray-based understanding of normal and malignant plasma cells.Ten years and counting: so what do we know about t(4;14)(p16;q32) multiple myeloma.Mechanisms of epigenetic deregulation in lymphoid neoplasms.Gene expression profiles of tumor biology provide a novel approach to prognosis and may guide the selection of therapeutic targets in multiple myeloma.The molecular characterization and clinical management of multiple myeloma in the post-genome era.Exploiting the Epigenome to Control Cancer-Promoting Gene-Expression Programs.Plasma membrane proteomics identifies biomarkers associated with MMSET overexpression in T(4;14) multiple myeloma.Genomics in multiple myeloma.The role of IGF-1 as a major growth factor for myeloma cell lines and the prognostic relevance of the expression of its receptorMMSET stimulates myeloma cell growth through microRNA-mediated modulation of c-MYC.The genetic architecture of multiple myeloma.AKT-mediated stabilization of histone methyltransferase WHSC1 promotes prostate cancer metastasis.Clinical impact of chromosomal aberrations in multiple myeloma.The use of molecular-based risk stratification and pharmacogenomics for outcome prediction and personalized therapeutic management of multiple myeloma.Genomic instability in multiple myeloma: mechanisms and therapeutic implications.Phase 2 study of dovitinib in patients with relapsed or refractory multiple myeloma with or without t(4;14) translocation.
P2860
Q24647037-930FB0FF-D9E8-48D2-B8AD-B089D0CDB8CEQ24670250-7835C86B-AF19-4C3F-B7E1-BC96D05DD937Q26769943-6B36912C-2A82-4B0C-AE13-317509313C53Q27024233-69D7A20D-15B8-4FC9-A9A1-D39AFD6A454DQ27851612-6B503C7B-53B2-4F75-B249-C72E6FE15FE9Q28268453-72B8FE8F-4887-48BC-BC4A-FF5D1F6B1383Q28296718-5CB421BD-3CED-4B83-9E67-290556DF1E05Q28678660-592C53E3-FED9-406D-B984-0798145C7B79Q30498959-6693ABA2-C1AA-4F4B-879B-F2F782C7D240Q33590961-3A3BEA81-E4C5-4274-97E3-DE6577E3488AQ33908640-2C673F5E-2A48-4282-B92F-D745F5F9F921Q34133622-B8EFB587-DEA0-4C31-B0B6-AA4A5D06342EQ34467171-E42D6DA4-560C-49C8-B57F-06F472625FA9Q34530992-3F473BDB-ECF6-4F6A-854E-9B0CB99FFA52Q34568855-C2D59182-497B-4952-B867-A26D96FDCC39Q34750568-9BCAB67F-754F-4FA5-AEEA-A60B26658A04Q35170930-8F89BBE6-06C6-4504-B3C0-0B4224023366Q35197437-271C08BB-E711-4365-928E-34454FBA34EEQ35220653-F96883B9-B8EC-4C91-8FA2-21F6FA889C71Q35569571-2AD4905A-9A1A-4F8A-BC77-1F2ED8790228Q35945858-3F8B674B-30B8-4437-B5B7-C68478945C9CQ36380235-F56D8F0F-D4A6-45F0-993A-713E7F656AB0Q36384699-93671E73-3C41-4465-9986-61A0038918CAQ36445523-DDCE8D66-4914-4BCE-889D-9C1D348BDB3AQ36453354-FBF41695-5415-42FF-9D0B-706A5CBA048CQ36654607-99B5C987-0980-4DAA-9C50-9A1165BC0263Q36873265-DD257BC2-2372-4669-AC8F-D8B5B6DF7244Q36938798-57E34E3F-8DAD-408E-82C4-5E7456B33EE5Q36939043-17CB1E4B-C5F6-41C0-87D4-7EC773A244DCQ36956610-FEFB04E7-D146-4E5B-9B0B-4C35EEC4D22EQ37138519-02D4718F-3368-4610-8577-B7E4285888D1Q37197359-D134C849-6999-4D99-B66E-F4302A961BF3Q37215171-18525211-7DD6-4600-80CA-7F55FBC7F1D9Q37458092-82D56F59-70E5-4CCE-B161-46746F33CAF4Q37718836-2BE6C666-966B-42D5-8BD1-0C0186D888E3Q37730639-1314996E-43FE-47D9-AE84-E05A631506C0Q37821077-0A145FF5-F977-4EFB-94CD-9F4E3B76C2E5Q37946246-5C888397-FDBC-48DF-B80E-38C0609E9739Q38115576-0296BEC0-773F-4FFB-AC66-20B3B36DFC57Q38268782-36939D5B-EEBC-474B-B711-DC3107D7960E
P2860
A subset of multiple myeloma harboring the t(4;14)(p16;q32) translocation lacks FGFR3 expression but maintains an IGH/MMSET fusion transcript
description
2003 nî lūn-bûn
@nan
2003 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի մարտին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
A subset of multiple myeloma h ...... an IGH/MMSET fusion transcript
@ast
A subset of multiple myeloma h ...... an IGH/MMSET fusion transcript
@en
A subset of multiple myeloma h ...... an IGH/MMSET fusion transcript
@nl
type
label
A subset of multiple myeloma h ...... an IGH/MMSET fusion transcript
@ast
A subset of multiple myeloma h ...... an IGH/MMSET fusion transcript
@en
A subset of multiple myeloma h ...... an IGH/MMSET fusion transcript
@nl
prefLabel
A subset of multiple myeloma h ...... an IGH/MMSET fusion transcript
@ast
A subset of multiple myeloma h ...... an IGH/MMSET fusion transcript
@en
A subset of multiple myeloma h ...... an IGH/MMSET fusion transcript
@nl
P2093
P1433
P1476
A subset of multiple myeloma h ...... an IGH/MMSET fusion transcript
@en
P2093
Erming Tian
Fenghuang Zhan
John Shaughnessy
Madhumita Santra
P304
P356
10.1182/BLOOD-2002-09-2801
P407
P577
2003-03-15T00:00:00Z